Axsome Therapeutics Files 8-K with Key Agreements and Sales
Ticker: AXSM · Form: 8-K · Filed: May 13, 2025 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K detailing new debt, equity sales, and agreement changes. Big moves happening.
AI Summary
On May 8, 2025, Axsome Therapeutics, Inc. entered into a material definitive agreement and simultaneously terminated another. The company also created a direct financial obligation and reported unregistered sales of equity securities. These events are detailed in their 8-K filing.
Why It Matters
This filing indicates significant corporate actions, including new financial obligations and equity sales, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 001-37635 — Commission File Number (Axsome Therapeutics' SEC identifier)
- 45-4241907 — IRS Employer Identification No. (Axsome Therapeutics' tax identifier)
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- May 08, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices City
FAQ
What specific material definitive agreement did Axsome Therapeutics enter into?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What was the nature of the terminated material definitive agreement?
The filing states that a material definitive agreement was terminated, but the specifics of this termination are not detailed in the provided text.
What type of direct financial obligation was created by Axsome Therapeutics?
The filing reports the creation of a direct financial obligation, but the exact nature or amount of this obligation is not specified in the excerpt.
Were the unregistered sales of equity securities registered with the SEC?
No, the filing explicitly mentions 'Unregistered Sales of Equity Securities,' indicating they were not registered.
What is the principal executive office address for Axsome Therapeutics?
The principal executive offices are located at One World Trade Center, 29th Floor, New York, New York, 10007.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Axsome Therapeutics, Inc. (AXSM).